左炔诺孕酮宫内缓释系统治疗子宫腺肌症的临床观察  

Clinical outcomes of levonorgestrel-releasing intrauterine system in treating adenomyosis

作　　者：滕芳[1] 李瑜[1] 傅士龙[1] 周德兰[1] 卫红[1] 周玲[1] 韩素萍[1] 

机构地区：[1]南京医科大学第一附属医院妇产科,210036

出　　处：《江苏医药》2010年第13期1520-1523,共4页Jiangsu Medical Journal

摘　　要：目的探讨左炔诺孕酮宫内缓释系统(LNG-IUS)治疗子宫腺肌症的临床疗效。方法 44例子宫腺肌症患者宫内放置LNG-IUS治疗,随访12个月,观察其临床疗效、生活质量和不良反应。结果放置LNG-IUS后经量PBAC评分明显减少[(167.43±170.88)分vs.(10.25±11.87)分](P<0.05)。痛经程度VAS评分[(80.23±29.21)分vs.(12.33±22.02)分]和VRS评分[(1.95±1.26)分vs.(0.14±0.52)分]均明显减少(P<0.05)。B超显示放置后子宫体积稍有缩小。置环后不良反应发生率为95.5%(阴道点滴出血率88.6%,闭经率18.2%)。81.8%的患者生活质量明显提高,总体满意度为90.9%。结论 LNG-IUS治疗子宫腺肌症疗效显著,无严重不良反应。Objective To evaluate the efficacy of levonorgestrel-releasing intrauterine system（LNG-IUS） in the treatment of adenomyosis.Methods LNG-IUS was inserted into uterine cavity in 44 women with adenomyosis.The patients were followed up for 12 months and clinical outcomes were evaluated.Results Compared to before,the menstrual blood volume by PBAC was decreased／[（167.43±170.88） points vs.（10.25±11.87） points／]（P0.05）.So did the visual analogue scale（VAS）／[（80.23±29.21）points vs.（12.33±22.02）points／] and verbal rating scale （VRS）／[（1.95±1.26）points vs.（0.14±0.52）points／] scores for the severity of dysmenorrhea（P0.05）.The mass of the uterus on B sonography decreased slightly.The incidence of adverse effects was 95.5% including persistent prolonged spotting in 88.6% and amenorrheic in 18%.The quality of life improved in 81.8% of the patients.A total of 40 women（90.9%） was satisfied with the treatment.ConclusionTreatment of adenomyosis with LNG-IUS is an effective conservative method without severe adverse response.

关 键 词：左炔诺酮宫内缓释系统 子宫腺肌症 

分 类 号：R711[医药卫生—妇产科学]